

Technology Advisory Committee C Interests Register

Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]

Publication Date: 28/04/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr Prithwiraj Das	Committee Member	Non-financial professional & personal	<p>At the time of the first Committee meeting, Prithwiraj worked for the pharmaceutical company Boehringer Ingelheim Ltd as the Market Access Lead for Specialty Therapies. He had not worked in the indication under consideration in the previous twelve months.</p> <p>Prior to the second meeting for this appraisal Prithwiraj left his role at Boehringer Ingelheim Ltd and from 18/01/2021 has been employed by a different pharmaceutical company. Prithwiraj confirmed that neither company is the manufacturer or a comparator in this appraisal.</p>	16.06.2020 29.12.2020	07.07.2020 12.01.2021	N/A	It was agreed that these declarations would not prevent Prithwiraj from participating in discussions on this appraisal.

Professor Matthew Stevenson	Committee member	Financial	Matthew gave advice to the previous company who manufactured carfilzomib, directly related to this topic. This was more than five years ago.	11.06.2020	07.07.2020	N/A	It was agreed that this declaration would not prevent Matthew from participating in discussions on this appraisal.
Dr Andrea Manca	Committee member	Non-financial professional & personal	Andrea is a co-investigator in a NIHR PGfAR grant in multiple myeloma.	16.06.2020	07.07.2020	N/A	It was agreed that this declaration would not prevent Andrea from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee member	Financial	Richard has been a PI on trials and attended paid advisory boards for Novartis in an unrelated area.	16.12.2020	12.01.2021	N/A	It was agreed that this declaration would not prevent Richard from participating in discussions on this appraisal.
Dr Karthik Ramasamy	Clinical expert	Financial	Karthik has attended advisory boards and received lecture fees from Amgen and his employer has received a trial grant from Amgen.	17.09.2019	07.07.2020	N/A	It was agreed that this declaration would not prevent Karthik from providing expert advice on this appraisal.

Shelagh McKinlay	Patient expert	Financial	Shelagh's employer Myeloma UK has received funding from Amgen.	20.09.2019	07.07.2020	N/A	It was agreed that this declaration would not prevent Shelagh from providing expert advice on this appraisal.
---------------------	----------------	-----------	--	------------	------------	-----	---